Posts by Yin, Jiale

The 27th National Conference of Clinical Oncology and 2024 CSCO Academic Annual Meeting, jointly organized by the Chinese Society of Clinical Oncology and the Beijing Xisike Clinical Oncology Research Foundation, was successfully held in Xiamen from September 25 to 29, 2024. The conference included multiple sessions on lung cancer, which brought together the latest advances and frontiers in lung cancer research from both domestic and international perspectives. During the conference, Oncology Frontier invited Dr. Wenhua Liang from The First Affiliated Hospital of Guangzhou Medical University to share new clinical developments in immunotherapy combinations for non-small cell lung cancer (NSCLC) and recent breakthroughs in precision diagnostic pathways.

At the 2024 European Society for Medical Oncology (ESMO) Annual Meeting, in the session dedicated to basic science and translational research, researchers presented groundbreaking findings on driver mutations in pancreatic cancer and their role in predicting patient prognosis and treatment response. The research highlighted significant differences in the diversity of driver gene mutations between healthy pancreatic tissue and tumor tissue, suggesting these differences play a crucial role in the formation and progression of pancreatic cancer. These findings also provide an important basis for personalized treatment. Dr. Francisco Martínez-Jiménez from Vall d'Hebron Barcelona Hospital Campus , Spain, interpreted the main research findings and discussed their clinical implications.

With advancements in breast cancer diagnosis and treatment, alongside the increasing diversity of patient needs, a comprehensive evaluation of treatment outcomes and improved quality of life have become focal points in this field. In recent years, Patient-Reported Outcomes (PROs) have emerged as a novel evaluation tool, playing an increasingly important role in breast cancer care. PROs go beyond traditional objective assessments like imaging and lab tests by emphasizing patients' subjective experiences, offering a new lens for both clinicians and patients to evaluate treatment effectiveness and quality of life. At the 2024 Breast Cancer Standardized Diagnosis and Quality Control Conference, Oncology Frontier interviewed Dr. Quchang Ouyang from Hunan Cancer Hospital to discuss the current applications, future trends, and significance of PROs in enhancing breast cancer diagnosis and treatment.

On October 18-19, 2024, the CACA Integrative Gastric Cancer Conference was held in Wuhan, bringing together multidisciplinary experts from around the world to discuss the latest advances, standards, and research developments in gastric cancer diagnosis and treatment.During the conference, Oncology Frontier interviewed Dr. Xiangdong Cheng, Secretary of Zhejiang Cancer Hospital. Professor Cheng shared insights into the role of the oral-gastric microbiome in gastric cancer and the progress of his research on clinical applications. Based on his extensive clinical experience, Professor Cheng also offered valuable career guidance for young physicians. Here are the highlights of the discussion:

On October 18-19, 2024, the CACA Integrated Gastric Cancer Conference concluded successfully in Wuhan, gathering global authorities in gastric cancer to discuss the latest advancements, pioneering developments, and standardized protocols for gastric cancer treatment. During the event, the Chinese Anti-Cancer Association Gastric Cancer Professional Committee (CGCA) completed its transition, electing Dr. Lin Chen from Peking University International Hospital as the new Chairman.Oncology Frontier had the privilege to conduct an in-depth interview with Dr. Lin Chen at the conference to discuss the future priorities and development strategies for the CGCA.

On October 19-20, 2024, the first stop of the "St. Gallen Breast Cancer Conference (SGBCC) China Tour" was held in Nanjing. This series of events, organized by the Breast Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO), the Beijing CSCO Clinical Oncology Research Foundation, the Beijing Kexin Medical Development Foundation, and the Jiangsu Anti-Cancer Association, and hosted by Jiangsu Provincial  Hospital, facilitated the exchange of knowledge between Chinese and foreign experts and laid the foundation for updating the new "St. Gallen International Expert Consensus." As the first Chinese female expert to join the SGBCC expert team, Dr. Yongmei Yin from Jiangsu Provincial Hospital initiated and promoted the "SGBCC China Tour" series to elevate global standards in breast cancer diagnosis and treatment, showcasing the strength of Chinese female experts. Oncology Frontier has invited Dr. Yongmei Yin to share her motivation behind organizing this series and her future plans.

The 2024 CACA Integrative Gastric Cancer Conference was held in Wuhan from October 18-19, bringing together domestic and international experts across multiple disciplines in gastric cancer. Oncology Frontier had the privilege to interview Dr. Kaixiong Tao, Executive Chair of this year’s conference and Professor from Wuhan Union Hospital of China. Prof. Tao discussed the core principles of integrative medicine and highlighted the conference's major themes. His profound clinical expertise and insights offered invaluable guidance for advancing gastric cancer treatment.